## Appendix One Angus HSCP Prescribing Management Plan: Active Interventions 2019/20

Initiative	Rationale	Actions	Lead	Status (RAG)
	Being d	ynamic to change		
Practice review report 18/19	Provision of key information to practices to enable discussion and identify areas to address	Audits and claims for all actions completed to be submitted by 31 <sup>St</sup> January 2019	RG	
		Audits to be used to further inform/adjust 2019/20 priorities	SJ	
Practice review report 19/20	Provision of key information to practices to enable discussion and identify areas to address	Plans to be issued to practices by 1 May 2019	SJ	
		Practice priorities for action in 2019/20 to be submitted to HSCP	MLR	
		by 1 <sup>st</sup> June 2019		
		Audits and claims for all actions completed to be submitted by 31 <sup>St</sup> Dec 2019	RG	
		Audits to be used to inform 2020/21 priorities	SJ	
Maintaining momentum	To maintain profile and momentum around prescribing position in relation to prescribing	Prescribing as a standing item with a written report at each Clinical Partnership Group meeting.	SJ/MLR	
		Continued review of top 50 GIC every quarter to monitor and adapt ongoing plans.	SJ	
		Annual PLT programme on prescribing topics to support high quality prescribing and realistic medicine	RG/SJ	
		Increase links with non-medical prescribers to maintain best value prescribing choices across all prescribers	KF	
Monitoring of formulary compliance	Formulary choices are based upon cost effectiveness and clinical best practice	Quarterly review of data by cluster and Angus wide, inclusion within Clinical Group reporting where required.	MLR/BM	
Establishment of Prescribing of Non- Medicines Advisory Group	To ensure cost effective use of prescribed non- medicines	A regional group co-chaired by Angus' Prescribing Clinical Lead, will identify further areas of improvement for Non-medicines prescribing within 2018/19	SJ	
		Rapid adoption of novel non- medicine supply routes which come from PONMAG reviews	SJ/RG	

Technical prescribing efficiencies	Ensure opportunities are identified to maximise technical efficiencies/switches	Regionally coordinated and locally implemented switches are expedited where clinically safe and approved by local prescribing leads. E.g. emollients, tramadol MR, vitamin D, nifedipine, diltiazem, Aveeno	SJ/MLR/HS /MB	
Horizon scanning	Ensure early identification in event of pricing changes and/or local deterioration in prescribing position	Clinical lead and Prescribing Support Unit monitoring	SJ/MB	

	Making best use of resources				
Pharmacotherapy service development	A requirement of the 2018 GMS contract we will create capacity and the potential to support improved shared learning in prescribing and management of prescribing processes across Angus.	Implementation of the pharmacotherapy actions as outlined in the Primary Care Improvement Plan.	MLR/AC/RG		
Improved prescribing of psychotropics through improved mental health pathways	Key priority for 2018/19 regionally recognising impact of mental health prescribing on variation and spend- with risk in some cases of harm	Angus will support the optimised use of psychotropic medications and making best use of non-drug options. Integrate psychiatric services to clusters with improved signposting to non-drug options.	BT/AC/SJ		
Diabetes Pathway Reviews	Key regional priority for 2018/19 recognising variation in spend and potential harm	Angus will support the development, testing and implementation of new regional pathways with an increased emphasis on supporting lifestyle changes and a more personalised approach to diabetes management. (including CCP testing). Cluster based delivery of all diabetes care.	CS/AC/SJ/RG		
Improved access to non- drug options	To reduce harms of medications and improve access to non- drug options across Angus	In line with nGMS contract to continue implementation of level 1 mental health support, physiotherapy and social prescribing within practices	RG/AC		
Supply of non- medicines to care homes	To improve cost effective supply chain	Increased support to care homes/nursing homes to source all non-medicines via PECOS where possible	DD		

		ement of Practice Prescribing		
Medicines of low clinical value	Support cost effective and efficient prescribing	Angus will support the planning process regionally and ensure implementation of recommendations locally. Sun cream, cod liver oil, omega 3, toothpaste, mouthwash, Saline nasal spray	SJ	
P-DQIP	Improved use of P-DQIP will can improve the safety pf prescribing	Ongoing roll-out of P-DQIP to practices. Integration of this tool within Pharmacist polypharmacy reviews. Should be prioritised, cluster QI by picking the top 5 for each Cluster	MLR	
	Supporting Ef	fective Communications		
Improve both internal and external communication of prescribing changes	To ensure accurate and consistent communication re current status to all	Ongoing updates of ScriptSwitch to reflect current prescribing plans	SJ	
	prescribers and public members in Angus	Primary Care Prescriber bulletin developed monthly by Prescribing Lead and circulated to all prescribers	SJ	
		Monthly update to CPG on prescribing status	MLR/SJ	
		Technical switches discussed with practice lead prior to initiation	MLR/MB	
		Series of public communications plan which are complimentary to NHS Tayside wide communication plans. Indication for each medicine.	AC	

GP Prescribing Initiatives			
Polypharmacy	Harm associated with polypharmacy is well evidenced.	Practices encouraged to consider pharmacist supported and GP led Level 3 polypharmacy reviews for high risk community patients. Care homes polypharmacy levels reported.	
		Cluster driven prescribing quality improvement and reducing harmful prescribing driven by indicators within PDQIP.	
Gabapentinoid/opiate review	To improve safe prescribing.	Review of patients on >120mg opiate and/or Gabapentinoid	

High cost psychotropics	High spend, not always maximised non-drug options.	Review of high cost psychotropic prescribing. Where not recently reviewed consider whether still indicated, on formulary and if needing mental health support. Ensure non-drug options	
Pharmacy team- led initiative support	GP awareness and support will be critical to effective delivery of all pharmacy- led initiatives.	GPs to support pharmacy teams in the delivery of the pharmacy-led initiatives. The format of this support is of course up to each practice team.	
Pharmacy team-led Initiatives			
High value, non- formulary prescribing monitoring	Identify scale and governance processes related to this area of prescribing	All high value-non-formulary prescribing reviewed by practice pharmacy teams on searches done by JM/SJ. Where agreed assurance will be sought to affirm the ongoing prescribing.	
Rivastigmine patch to tablet	To improve cost effective prescribing	Where feasible prescribe tablet instead of patch. Need to d/w James Shaw	
Eplerenone/spironolact one review	To ensure cost effective prescribing	Where it has not been prescribed first line, patients should be switched to spironolactone	
Blood glucose testing in those on metformin/no anti- glycaemic except within DVLA guidance	To only prescribe blood glucose monitoring where evidence supports use or legislation mandates	To review all patients on blood glucose monitoring sundries to ensure prescribing is indicated.	
Perindopril switch to lisinopril/ramipril	To ensure the most cost- effective form is being prescribed	Switch patients on perindopril to Ramipril equivalent having proven concept (Lour Rd)	
Calcium/vit D use for those without osteoporosis/osteopae	To ensure those receiving calcium/vit D require it	Stopping and suggesting vitamin D OTC. Where on Accrete BD, this can be switched to Accrete one a day.	
Top 60 GIC non-standard drug form review	To ensure all forms of drugs prescribed in top 50 GIC are most cost effective	JM to extract any patients prescribed a non- cost- effective drug form of medicine appearing in Top 60 GIC to ensure this was intended	
ScriptSwitch	To review all high value declines	JM to review high value declines to ensure consideration being given to the more cost- effective form	
Nitrofurantoin	Variation in practice pan Angus. Risks associated with long term use.	Practices encouraged to consider reviewing all patients on <b>repeat</b> <b>prescriptions</b> .	
Bisphosphonate	Optimal use of medication	Assure use is within national guidelines including treatment duration, indication and reviewing of QFracture risk (shared with GP management)	

NHS Tayside specialist service Wound and catheter care	Potential reduction in costs and wastage associated with moving from prescribing wound/catheter care to accessing via stock order	Service manager in Angus tasked with scoping, implementing and maximising roll out of regional programme in Angus.	
		PONMAG review to improve formulary prescribing rates of wound care and catheter products across NHS Tayside	
Stoma Accessories	Supported review of all patients to ensure management in line with revised formulary	Test process in one Angus practice	
		Complete Angus roll out	
		Extend to include stoma bags in 2019/20	
Specialist baby milk	Increased prescribing possibly leading to over- diagnosis	PONMAG review began Sept 18	
Diabetes consumables	Improved use of diabetes consumables in line with NHST formulary	PONMAG review began November 18	
Analgesics/chronic pain	Highest spending area on medicines for NHS Tayside is analgesics	PMG to develop wider plans to continue to address this	

## Lead abbreviations

- AC Dr Alison Clement, Clinical Director Angus HSCP
- SJ SJ- Dr Scott Jamieson, Prescribing Lead Angus HSCP
- MLR Michelle Logan-Rena, Pharmacy Lead Angus
- BT- Bill Troup, Head of Service, Mental Health RG Primary Care Manager, Angus HSCP
- DD Doreen Donald, Service Lead Community Nursing
- HS Hazel Steele, Lead Pharmacist, Prescribing Support
- KF Karen Fletcher, Lead Nurse, Angus HSCP
- JM Jenna Murray, Prescribing Support Pharmacy Technician
- BM Brian McGregor, Pharmacy Data Analyst, PSU NHS Tayside
- CS Dr Chris Schofield, Consultant Endocrinologist
- MB Mark Batey, Prescribing Support Technician, NHS Tayside